Showing results (131-140 of 153) with videos related to
Sort By:
Pageof 16
Therapeutic Advances in Medical Oncology|December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancerUlrike Nitz, Oleg Gluz, Hans H Kreipe, et al.Gastroenterology|March 2, 2010
Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cellsFrederik J H Hoogwater, Maarten W Nijkamp, Niels Smakman, et al.Cancer Medicine|November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIsabel Grote, Stephan Bartels, Leonie Kandt, et al.International Journal of Cancer|February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrialsMonika Graeser, Simone Schrading, Oleg Gluz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2017
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETNadia Harbeck, Oleg Gluz, Matthias Christgen, et al.Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.Cancer Cell|September 13, 2011
Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acidsJeanine M L Roodhart, Laura G M Daenen, Edwin C A Stigter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialOleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.The Journal of Pathology. Clinical Research|April 15, 2024
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colonMalte Gronewold, Isabel Grote, Stephan Bartels, et al.The Journal of Clinical Investigation|July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-respondersGuokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.Pageof 16